Senseonics’ next-gen CGM
Senseonics (NYSE:SENS) has high expectations for its longer-duration CGM following positive results from the Promise study that were presented in June. After presenting the company’s third-quarter earnings, President & CEO Tim Goodnow said Senseonics hopes for FDA approval soon.
The next-generation Eversense CGM demonstrated matching performance levels compared to the current 90-day sensor available in the U.S., but with reduced calibration, down to one per day, with duration extended to 180 days. The company says its system offers a fluorescence-based sensor, a smart transmitter worn over the sensor for facilitating data communication and a mobile app that displays glucose values, trends and alerts.
Senseonics touts Eversense as the first CGM system to feature a smart transmitter that gives wearers discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor.
“We are encouraged by the excitement demonstrated by patients and HCPs for the 180-day sensor in the U.S. and we are pleased with the progression of the review and are hopeful the FDA will reach an approval decision in the coming months based on the positive Promise study results,” Goodnow said. “We look forward to launching the new system shortly after approval.”